Abstracts tagged "P. Gingivalis"

Abstract Number: 1369 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Porphyromona Gingivalis Serology In Rheumatoid Arthritis and Non-Rheumatoid Inflammatory Disease
Mélanie Rinaudo-Gaujous¹, Adeline Moreau¹, Vincent Blasco-Baque², Xavier Roblin³, Christian Genin¹, Thierry Thomas⁴, Stéphane Paul¹ and Hubert Marotte⁵, ¹Laboratory of Immunology and immunomonitoring, CIC CIE3 Inserm Vaccinology, GIMAP EA3064, Hôpital Nord, Saint-Etienne, France, ²Institute of Cardiovascular and Metabolic Diseases, CHU Rangueil, Toulouse, France, ³Department of gastroenterology, Hôpital Nord, Saint-Etienne, France, ⁴INSERM U1059 and University Hospital, Saint-Etienne, France, ⁵INSERM U1059 and University Hospital, Hôpital Nord, Saint-Etienne, France
Background/Purpose: Periodontal disease (PD) is associated mainly with rheumatoid arthritis (RA), but recent data suggest an association with ankylosing spondylitis (AS). Role of Porphyromonas gingivalis…
Abstract Number: 2417 • 2013 ACR/ARHP Annual Meeting
Antibodies To Porphyromonas Gingivalis Peptidylarginine Deiminase In Rheumatoid Arthritis Are Not Directed Against The Autocitrullinated Enzyme
Maximilian F. Konig¹, Alizay Paracha², Malini Moni¹, Clifton O. Bingham III¹ and Felipe Andrade¹, ¹Division of Rheumatology, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²The University of Oklahoma, Norman, OK
Background/Purpose: Porphyromonas gingivalis (Pg) has received considerable attention by investigators trying to explain the striking association of periodontal disease (PD) and rheumatoid arthritis (RA). Bacterial…
Abstract Number: 2425 • 2013 ACR/ARHP Annual Meeting
Impaired TNFá Production By Dendritic Cells From Rheumatoid Arthritis Patients Upon Contact With Porphyromonas Gingivalis
Kim CM Santegoets^1,2, Mark H. Wenink^1,2, Wim B van den Berg³ and Timothy RDJ Radstake^2,4, ¹Department of Rheumatology & Clinical Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ⁴Rheumatology & Clinical Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The prevalence of periodontitis is increased in patients with rheumatoid arthritis (RA) and the severity of periodontitis can affect the level of arthritis. Porphyromonas…
Abstract Number: 2430 • 2013 ACR/ARHP Annual Meeting
Antibodies To Porphyromonas Gingivalis as An Etiological Clue To The Development Of Anti-Citrullinated Protein Antibody Positive Rheumatoid Arthritis
Nastya Kharlamova¹, Natalia Sherina¹, Anne-Marie Quirke², Kaja Eriksson³, Lena Israelsson⁴, Jan Potempa⁵, Patrick Venables⁶, Tulay Yucel-Lindberg³ and Karin Lundberg⁷, ¹Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom, ³Department of Dentistry, Karolinska Institutet, Stockholm, Sweden, ⁴Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁵Microbiology Department, Jagiellonian University, Krakow, Poland, ⁶Kennedy Institute of Rheumatology, Oxford, United Kingdom, ⁷Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the production of autoantibodies to citrullinated proteins (ACPA). Citrullinated proteins are generated by the actions of peptidyl arginine…
Abstract Number: 2409 • 2013 ACR/ARHP Annual Meeting
Association Of High Serum Interleukin-23 Levels With Porphyromonas Gingivalis Antibodies In Patients With Early Rheumatoid Arthritis
Sheila L. Arvikar¹, Klemen Strle², Deborah S. Collier³, Mark C. Fisher¹, Toshihisa Kawai⁴, Jose U. Scher⁵ and Allen C. Steere⁶, ¹Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Rheumatology, Massachusetts General Hospital, Boston, MA, ⁴Forsyth Institute, Cambridge, MA, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶Medicine, Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased frequency of periodontal disease (PD) and antibodies to P. gingivalis (Pg), a major periodontal pathogen. Both…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].